Pephexia Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.16M
- Investors
-
5
Pephexia Therapeutics General Information
Description
Developer of peptide-based pharmacotherapies intended to treat cachexia, sarcopenia, and related diseases. The company specializes in providing effective pharmacotherapy for the treatment of cachexia based on naturally occurring peptide hormones, enabling medical practitioners to treat and improve the quality of life of patients suffering from chronic pulmonary, heart, and kidney diseases.
Contact Information
Website
www.pephexia.comCorporate Office
- Nordre Fasanvej 215
- Frederiksberg C
- 2000 Frederiksberg
- Denmark
Corporate Office
- Nordre Fasanvej 215
- Frederiksberg C
- 2000 Frederiksberg
- Denmark
Pephexia Therapeutics Timeline
Pephexia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 07-Jul-2025 | $1.16M | Completed | Startup | ||
| 4. Grant | 07-Feb-2024 | Completed | Startup | |||
| 3. Grant | 09-Mar-2022 | Completed | Startup | |||
| 2. Debt - General | 01-Dec-2021 | $460K | $2.05M | Completed | Startup | |
| 1. Accelerator/Incubator | 23-Sep-2021 | $1.59M | $1.59M | Completed | Startup |
Pephexia Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pephexia Therapeutics Patents
Pephexia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024408735-A1 | Selective npy5r agonists with high chemical and metabolic stability | Pending | 21-Dec-2023 | ||
| EP-4828715-A1 | Selective npy5r agonists with high chemical and metabolic stability | Pending | 21-Dec-2023 | ||
| WO-2025133085-A1 | Selective npy5r agonists with high chemical and metabolic stability | Inactive | 21-Dec-2023 | ||
| WO-2024003381-A1 | Hybrid polypeptides acting as dual ghsr and npy5r agonists | Inactive | 01-Jul-2022 | ||
| WO-2023161226-A1 | Ghrelin agonists with improved potency | Inactive | 22-Feb-2022 | C07K14/60 |
Pephexia Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pephexia Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eurostars | Other | |||
| Danish Business Innovation Fund | Government | |||
| Innovationsfonden | Accelerator/Incubator | |||
| BioInnovation Institute | Accelerator/Incubator | |||
| Denmark's Export and Investment Fund | Venture Capital | Minority |
Pephexia Therapeutics FAQs
-
When was Pephexia Therapeutics founded?
Pephexia Therapeutics was founded in 2020.
-
Where is Pephexia Therapeutics headquartered?
Pephexia Therapeutics is headquartered in Frederiksberg, Denmark.
-
What is the size of Pephexia Therapeutics?
Pephexia Therapeutics has 8 total employees.
-
What industry is Pephexia Therapeutics in?
Pephexia Therapeutics’s primary industry is Drug Discovery.
-
Is Pephexia Therapeutics a private or public company?
Pephexia Therapeutics is a Private company.
-
What is Pephexia Therapeutics’s current revenue?
The current revenue for Pephexia Therapeutics is .
-
How much funding has Pephexia Therapeutics raised over time?
Pephexia Therapeutics has raised $2.05M.
-
Who are Pephexia Therapeutics’s investors?
Eurostars, Danish Business Innovation Fund, Innovationsfonden, BioInnovation Institute, and Denmark's Export and Investment Fund have invested in Pephexia Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
